TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

Core Insights - TransCode Therapeutics has appointed Dr. Michel Janicot as Senior Development Officer to enhance its oncology pipeline and drug development efforts [1][3] - Dr. Janicot brings over 35 years of experience in pharmaceutical research and drug development, particularly in oncology [1][2] - The company focuses on innovative RNA-based therapies for advanced malignancies, with lead candidates TTX-MC138 and Seviprotimut-L targeting metastatic and recurrent cancers [1][5] Company Overview - TransCode Therapeutics specializes in immuno-oncology and targeted cancer therapies, aiming to treat advanced malignancies [5] - The lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a known biomarker for metastasis [5] - The company has a portfolio of first-in-class therapeutic candidates designed to activate the immune system against cancer cells [5] Leadership and Expertise - Dr. Janicot has a Ph.D. in Biochemistry and has held senior leadership roles in major pharmaceutical companies, including Janssen Pharmaceutica [1][4] - He has founded a consulting firm and co-founded a nonprofit focused on pediatric oncology drug development, showcasing his commitment to advancing cancer therapies [2][4] - His role at TransCode will involve supporting strategic R&D initiatives and clinical development strategies for investigational oncology programs [3][4]